Monitoring the safety of COVID-19 vaccination in pregnancy in the UK: A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems

TY - JOUR

T1 - Monitoring the safety of COVID-19 vaccination in pregnancy in the UK

T2 - A national study using the UK Obstetric Surveillance System (UKOSS), UK Teratology Information Service (UKTIS) and Vaccination in Pregnancy (VIP) safety monitoring systems

AU - Richardson, Jonathan L.

AU - Stephens, Sally

AU - Chappell, Lucy C.

AU - Campbell, Helen

AU - Amirthalingam, Gayatri

AU - O’Boyle, Shennae

AU - Bukasa, Antoaneta

AU - Knight, Marian

AU - Hodson, Kenneth K.

N1 - Funding Information: The Spanish Government supported this work through projects CICYT MAT97-0-986-C02-02 and DGCYT PB91-0554. Publisher Copyright: © The Author(s) 2022.

PY - 2022

Y1 - 2022

N2 - Background: COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection. Methods: Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021. Results: There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%). Conclusion: Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.

AB - Background: COVID-19 vaccines are protective against disease. Pregnant women benefit from vaccination as they are at higher risk of poor maternal and neonatal outcomes following infection. Methods: Following regulatory approval of two COVID-19 vaccines in the United Kingdom, a rapid national study of vaccination in pregnancy was instituted using three existing safety surveillance platforms: UKOSS, UKTIS and VIP. This preliminary report describes the data collected up to the 15th June 2021. Results: There were 971 reports of COVID-19 vaccination in the UKOSS/UKTIS (n = 493) and VIP (n = 478) monitoring systems describing 908 individual pregnancies. Pfizer-BioNTech mRNA vaccination was most common (n = 501, 55.2%), most women were vaccinated in their second or third trimester (n = 566, 62.3%), and were mainly vaccinated due to occupational infection risk (n = 577, 63.5%). Conclusion: Obstetric outcome data will be obtained by December 2021. However, women should not delay vaccination whilst awaiting further safety data to emerge.

KW - COVID-19 vaccine

KW - obstetric surveillance

KW - pharmacovigilance

KW - pregnancy

KW - SARS-coV-2

KW - teratology

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85124872483&partnerID=8YFLogxK

U2 - 10.1177/1753495X221076713

DO - 10.1177/1753495X221076713

M3 - Article

AN - SCOPUS:85124872483

SN - 1753-495X

JO - Obstetric Medicine

JF - Obstetric Medicine

ER -